Deficiency of a New Protein Associated with Cardiac Syndrome X; Called Adropin. Issue 3 (18th April 2013)
- Record Type:
- Journal Article
- Title:
- Deficiency of a New Protein Associated with Cardiac Syndrome X; Called Adropin. Issue 3 (18th April 2013)
- Main Title:
- Deficiency of a New Protein Associated with Cardiac Syndrome X; Called Adropin
- Authors:
- Celik, Ahmet
Balin, Mehmet
Kobat, Mehmet Ali
Erdem, Kenan
Baydas, Adil
Bulut, Musa
Altas, Yakup
Aydin, Suna
Aydin, Suleyman - Abstract:
- <abstract abstract-type="main" id="cdr12025-abs-0001"> <title>Summary</title> <p>The pathophysiology of cardiac syndrome X (CSX) is still unclear, but most patients with CSX have endothelial dysfunction. It has been shown that adropin uniquely effects the regulation of endothelial function. The purpose of the study was to evaluate the role of adropin in CSX. Eighty‐six consecutive cardiac syndrome X‐diagnosed patients and 86 age‐sex matched healthy subjects were enrolled into the study. Serum adropin levels, nitrite/nitrate levels were measured in each subject. The adropin levels were significantly lower in patients with CSX than healthy subjects (1.7 ± 0.8 ng/mL and 3.4 ± 1.8 ng/mL, respectively; <italic>P</italic> &lt; 0.001). The BMI values of patients with CSX were significantly higher than control subjects (28.1 ± 2.4 kg/m<sup>2</sup> and 26.0 ± 3.7 kg/m<sup>2</sup>, respectively; <italic>P</italic> &lt; 0.001). Plasma nitrite/nitrate levels were lower in patients with CSX than control subjects (15.9 ± 1.6<bold> </bold>μmol/L vs. 25.4 ± 2.8 μmol/L, respectively; <italic>P</italic> &lt; 0.001), and they have a significantly positive correlation with plasma adropin levels (r = 0.463, <italic>P</italic> &lt; 0.001). In the multiple linear regression analysis, nitrite/nitrate levels, BMI, and adropin were found to be independent risk factors for CSX. A ROC curve is used to identify the ability of adropin levels to predict the cardiac syndrome X. The area under the ROC curve<abstract abstract-type="main" id="cdr12025-abs-0001"> <title>Summary</title> <p>The pathophysiology of cardiac syndrome X (CSX) is still unclear, but most patients with CSX have endothelial dysfunction. It has been shown that adropin uniquely effects the regulation of endothelial function. The purpose of the study was to evaluate the role of adropin in CSX. Eighty‐six consecutive cardiac syndrome X‐diagnosed patients and 86 age‐sex matched healthy subjects were enrolled into the study. Serum adropin levels, nitrite/nitrate levels were measured in each subject. The adropin levels were significantly lower in patients with CSX than healthy subjects (1.7 ± 0.8 ng/mL and 3.4 ± 1.8 ng/mL, respectively; <italic>P</italic> &lt; 0.001). The BMI values of patients with CSX were significantly higher than control subjects (28.1 ± 2.4 kg/m<sup>2</sup> and 26.0 ± 3.7 kg/m<sup>2</sup>, respectively; <italic>P</italic> &lt; 0.001). Plasma nitrite/nitrate levels were lower in patients with CSX than control subjects (15.9 ± 1.6<bold> </bold>μmol/L vs. 25.4 ± 2.8 μmol/L, respectively; <italic>P</italic> &lt; 0.001), and they have a significantly positive correlation with plasma adropin levels (r = 0.463, <italic>P</italic> &lt; 0.001). In the multiple linear regression analysis, nitrite/nitrate levels, BMI, and adropin were found to be independent risk factors for CSX. A ROC curve is used to identify the ability of adropin levels to predict the cardiac syndrome X. The area under the ROC curve was 0.854 for adropin levels (<italic>P</italic> = 0.0001). The sensitivity and specificity values of adropin levels were 90.7 and 70.9%, respectively (cut‐off value 2.73). In conclusion, lower serum adropin levels were associated with CSX. Adropin is an independent risk factor for CSX.</p> </abstract> … (more)
- Is Part Of:
- Cardiovascular therapeutics. Volume 31:Issue 3(2013:Jun.)
- Journal:
- Cardiovascular therapeutics
- Issue:
- Volume 31:Issue 3(2013:Jun.)
- Issue Display:
- Volume 31, Issue 3 (2013)
- Year:
- 2013
- Volume:
- 31
- Issue:
- 3
- Issue Sort Value:
- 2013-0031-0003-0000
- Page Start:
- 174
- Page End:
- 178
- Publication Date:
- 2013-04-18
- Subjects:
- Cardiovascular pharmacology -- Periodicals
Cardiovascular agents -- Periodicals
Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals
Cardiovascular Agents -- Periodicals
Cardiovascular Diseases -- drug therapy -- Periodicals
Agents cardiovasculaires -- Périodiques
Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques
616.1005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1755-5922 ↗
http://www.blackwell-synergy.com/loi/cath ↗
http://www.blackwellpublishing.com/journal.asp?ref=1755-5914&site=1 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/1755-5922.12025 ↗
- Languages:
- English
- ISSNs:
- 1755-5914
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3051.520500
British Library HMNTS - ELD Digital store - Ingest File:
- 3384.xml